The article argues that AI will revolutionize drug discovery long before it can streamline clinical development, creating an abundance of candidate molecules but leaving patient trials as the main constraint. As discovery becomes commoditized and more assets target the same biology, real value will hinge on predictive toxicity, clinical efficacy, and strategic trial design.

• Drug candidate pipelines have doubled in the past decade but novel FDA approvals stayed flat at ~50/year, proving clinical development—not discovery—is the real bottleneck.
• Preclinical assets license for tens of millions, but value jumps to hundreds of millions or low-billions post-Phase 2 proof of concept—a premium set to shrink as AI floods the pipeline with candidates.
• Competition per target is already intense (100+ programs on targets like PD-1/GLP-1) and could double or triple by 2030, making individual molecules less rare and pushing investors to demand better translational data and trial design.
• AI excels at data-rich, fast-feedback problems (virtual screening, protein folding) but struggles with messy, high-variability clinical questions (endpoint selection, immune response prediction, adaptive trials)—so real value will shift to whoever masters those still-slow areas.